Liver Cancer Medications

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.